CIS Insulin Market To Reach $4.67 Billion By 2030 | CAGR: 5.6%

CIS Insulin Market Growth & Trends

The CIS insulin market size is expected to reach USD 4.67 billion by 2030, registering a CAGR of 5.6% from 2024 to 2030, according to a new report by Grand View Research, Inc.  The presence of an extensive pipeline portfolio of products exhibiting higher efficacies and their subsequent commercialization over the next six years is expected to serve this market as a high impact rendering driver. The introduction of government initiatives aimed at improving the affordability of insulin via price reduction, such as the collaboration between the government of Ukraine and Indar to reduce the price of insulin by 20% in 2013 is expected to have positive influence on demand. Some of the other drivers of this market include increasing attempts made by manufacturers to capitalize on the untapped opportunities by opening new manufacturing units to improve the supply of insulin and growing incidence rates of type II diabetes are some of the factors expected to fuel future market growth.

 Request a free sample copy or view report summary: CIS Insulin Market Report

CIS Insulin Market Report Highlights

• Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats

• Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins.

• Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region.

• Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body's functions.

CIS Insulin Market Segmentation

Grand View Research has segmented the CIS insulin market on the basis of on product, type, application, distribution channel, and region:

CIS Insulin Product Outlook (Revenue, USD Million, 2018 - 2030)

• Rapid-acting Insulin

• Long-acting Insulin

• Combination Insulin

• Biosimilar

• Other Products

CIS Insulin Type Outlook (Revenue, USD Million, 2018 - 2030)

• Human Insulin

• Insulin Analog

CIS Insulin Application Outlook (Revenue, USD Million, 2018 - 2030)

• Type I Diabetes

• Type II Diabetes

CIS Insulin Distribution Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals Pharmacies

• Retail & Specialty Pharmacies

• Other Distribution Channels

CIS Insulin Regional Outlook (Revenue, USD Million, 2018 - 2030)

• Commonwealth of Independent States (CIS)

  • Russia

  • Poland

  • Turkey

  • Ukraine

  • Uzbekistan

  • Belarus

  • Kazakhstan

List of Key Players in the CIS Insulin Market

• Eli Lilly and Company

• Sanofi S.A.

• Boehringer Ingelheim International GmbH

• Oramed Pharmaceuticals Inc.

• Novo Nordisk A/S

• Merck & Co., Inc.

• Bristol-Myers Squibb Company

• Novartis AG